annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 22C Phase II study of bavituximab plus docetaxel in locally advanced or
metastatic breast cancer. (Abstract #1042)
D. Tabagari, G. Nemsadze, M. Janjalia, M. Jincharadze, J. Shan
Brd. 22D Risk of venous and arterial thromboembolic events in patients with
metastatic breast cancer treated with bevacizumab: A meta-analysis.
(Abstract #1043)
V. Calvo, N. Ramirez, C. Saura, M. Vidal, A. Velasco, A. Llombart-Cussac,
H. Cortes-Funes, D. Miles, J. Baselga, J. Cortes
Brd. 22E Use of fresh assessment of tumor-initiating cells in pleural fluid of breast
cancer patients to predict overall survival. (Abstract #1044)
W. A. Woodward, E. N. Cohen, H. Gao, L. Li, C. Jimenez, S. Krishnamurthy,
S. L. Tucker, M. Cristofanilli, T. A. Buchholz, J. M. Reuben
Brd. 22F Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to
chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC):
Metaregression analysis of randomized trials (RCT). (Abstract #1045)
F. Cuppone, E. Bria, I. Sperduti, V. Vaccaro, C. Nisticò, P. Carlini, M. Milella,
A. Fabi, D. Giannarelli, F. Cognetti
Brd. 22G Updated efficacy and safety assessment of first-line therapy with lapatinib,
trastuzumab, and paclitaxel in HER2� metastatic breast cancer. (Abstract
#1046)
F. J. Esteva, S. Franco, M. K. Hagan, A. Brewster, W. Williams, A. M. Florance,
K. Koch, S. J. Turner, M. Ridderheim, A. T. Perez
Brd. 22H High-throughput technologies to personalize medical treatment in patients
with metastatic breast cancer. (Abstract #1047)
R. Wolp-Diniz, J. De La Cruz, V. Scott, C. Richon, M. Campone, T. D. Bachelot,
F. Dalenc, V. Lazar, J. Soria, F. Andre
Brd. 23A Biomarkers as potential predictors of response to treatment with motesanib
or bevacizumab in combination with paclitaxel (P) in patients (pts) with
locally recurrent or advanced metastatic breast cancer (MBC). (Abstract
#1048^)
S. D. Patterson, M. T. Davis, J. R. Mackey, M. Martin, Y. Hei, M. B. Bass
Brd. 23B Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L)
in combination with docetaxel (D) and trastuzumab (T) in untreated HER2overexpressing
(HER�) metastatic breast cancer (MBC). (Abstract #1049)
V. Dieras, M. J. Kennedy, P. Tresca, M. E. Marty, H. Burris, M. DeSilvio,
N. O’Donovan, M. Lau, M. Ridderheim, J. Crown
Brd. 23C Use of serum uPA change to predict PFS and overall survival in first-line
trastuzumab-treated breast cancer. (Abstract #1050)
H. Y. Hou, U. Anyanwu, N. Jamshidi, K. Leitzel, S. M. Ali, W. Köstler, E. Fuchs,
P. Hamer, W. P. Carney, A. Lipton
Brd. 23D Maintenance of clinical efficacy following dose reduction of ixabepilone plus
capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T)
pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis
of pooled data from two phase III clinical studies (046/048). (Abstract #1051)
V. Valero, L. D. Bosserman, D. A. Yardley, H. H. Roche, E. Thomas, L. T. Vahdat,
P. Mukhopadhyay, D. M. Opatt, R. A. Peck, J. Sparano
Brd. 23E Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor,
in patients whose breast cancer is progressing on aromatase inhibitor
therapy. (Abstract #1052)
A. M. Wardley, R. Stein, J. McCaffrey, J. Crown, Z. Malik, D. Rea, P. J. Barrett-Lee,
G. T. Lee
Brd. 23F Association of receptor activator of NF-kb (RANK) expression with bone
metastasis in breast carcinomas. (Abstract #1053)
D. Santini, B. Vincenzi, A. Russo, C. Ortega, C. Porta, S. Galluzzo, N. M. La Verde,
C. Caroti, R. Addeo, G. Tonini
159
SATURDAY